Health care stocks were flat to lower pre-bell Monday, with The Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.
Revvity (RVTY) shares were down more than 9% after the company reported lower fiscal Q2 adjusted earnings and cut its fiscal 2025 non-GAAP EPS guidance.
Celcuity (CELC) stock was up more than 230% after the company said a phase 3 trial of its drug gedatolisib, combined with fulvestrant, with and without palbociclib, demonstrated a "statistically significant and clinically meaningful" improvement in progression-free survival in a type of breast cancer.
BeOne Medicines (ONC) stock was up more than 2% after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Tevimbra for treating adults with resectable non-small cell lung cancer at high risk of recurrence.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。